VPS33B late endosome and lysosome associatedGenealiases: KDIDAR · PFIC12
Q-omics provides the consensus-scored VPS33B profile across patient tissues and cancer cell-line models. VPS33B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, VPS33B is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, VPS33B RNA expression shows 19,287 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where VPS33B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPS33B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPS33B survival associations across molecular data types. VPS33B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPS33B RNA expression–survival associations across cancer types. High VPS33B expression shows unfavorable associations in MESO, HNSC and LIHC, but favorable associations in OV, SCLC and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for VPS33B RNA expression.
This table summarizes VPS33B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for VPS33B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPS33B shows higher tumor expression in HNSC, LIHC, BLCA, LUAD, STAD and COAD. The HNSC box plot shows higher VPS33B RNA expression in tumor versus normal tissue (log2 FC = +0.468, t-test p < 0.001).
This table shows molecular features associated with VPS33B in patient tissues and cancer cell lines. In patient samples, VPS33B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, VPS33B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
